ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Research Report 2026
Published Date: 2026-02-09
|
Report Code: QYRE-Auto-14N18507
Home | Market Reports
Global Adeno Associated Virus AAV Vector Production CDMO Market Research Report 2024
BUY CHAPTERS

Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Research Report 2026

Code: QYRE-Auto-14N18507
Report
2026-02-09
Pages:180
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Thermo Fisher Scientific
Lonza
Catalent
Charles River
Merck
SK pharmteco
Oxford BioMedica
AGC Biologics（MolMed）
Gene Universal
Polyplus (Sartorius)
CCRM
FUJIFILM Diosynth Biotechnologies
Biovian
Miltenyi Bioindustry
Aldevron
Takara Bio
Yposkesi
Genezen
Exthera
GenScript ProBio
EurekaBio
OBiO Technology
GeneSail Biotech
VectorBuilder
WuXi ATU
Ubrigene
Porton Biologics
Pharmaron
PackGene Biotechnology

Adeno-Associated Virus (AAV) Vector Production CDMO Market

The global Adeno-Associated Virus (AAV) Vector Production CDMO market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Adeno-Associated Virus (AAV) Vector Production CDMO (Contract Development and Manufacturing Organization) refers to companies that specialize in the development and large-scale production of AAV vectors, which are commonly used as gene therapy delivery systems. CDMOs provide a range of services including vector design, process development, scale-up, manufacturing, and quality control under Good Manufacturing Practices (GMP) standards. These organizations support biotechnology and pharmaceutical companies by producing clinical-grade AAV vectors for preclinical research, clinical trials, and commercial use, helping to meet the growing demand for gene therapies.
The North American market for Adeno-Associated Virus (AAV) Vector Production CDMO is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Adeno-Associated Virus (AAV) Vector Production CDMO is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Adeno-Associated Virus (AAV) Vector Production CDMO in Vaccine Development is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Adeno-Associated Virus (AAV) Vector Production CDMO include Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics（MolMed）, Gene Universal, Polyplus (Sartorius), etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Adeno-Associated Virus (AAV) Vector Production CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Adeno-Associated Virus (AAV) Vector Production CDMO. The Adeno-Associated Virus (AAV) Vector Production CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Adeno-Associated Virus (AAV) Vector Production CDMO market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Adeno-Associated Virus (AAV) Vector Production CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Adeno-Associated Virus (AAV) Vector Production CDMO Market Report

Report Metric Details
Report Name Adeno-Associated Virus (AAV) Vector Production CDMO Market
Segment by Type
  • Adherent Culture
  • Suspension Culture
Segment by Application
  • Vaccine Development
  • Gene Therapy
  • Academic Scientific Research Institution
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics（MolMed）, Gene Universal, Polyplus (Sartorius), CCRM, FUJIFILM Diosynth Biotechnologies, Biovian, Miltenyi Bioindustry, Aldevron, Takara Bio, Yposkesi, Genezen, Exthera, GenScript ProBio, EurekaBio, Obio Technology, GeneSail Biotech, VectorBuilder, WuXi ATU, Ubrigene, Porton Biologics, Pharmaron, PackGene Biotechnology
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Adeno-Associated Virus (AAV) Vector Production CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Adeno-Associated Virus (AAV) Vector Production CDMO Market report?

Ans: The main players in the Adeno-Associated Virus (AAV) Vector Production CDMO Market are Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, SK pharmteco, Oxford Biomedica, AGC Biologics（MolMed）, Gene Universal, Polyplus (Sartorius), CCRM, FUJIFILM Diosynth Biotechnologies, Biovian, Miltenyi Bioindustry, Aldevron, Takara Bio, Yposkesi, Genezen, Exthera, GenScript ProBio, EurekaBio, Obio Technology, GeneSail Biotech, VectorBuilder, WuXi ATU, Ubrigene, Porton Biologics, Pharmaron, PackGene Biotechnology

What are the Application segmentation covered in the Adeno-Associated Virus (AAV) Vector Production CDMO Market report?

Ans: The Applications covered in the Adeno-Associated Virus (AAV) Vector Production CDMO Market report are Vaccine Development, Gene Therapy, Academic Scientific Research Institution, Others

What are the Type segmentation covered in the Adeno-Associated Virus (AAV) Vector Production CDMO Market report?

Ans: The Types covered in the Adeno-Associated Virus (AAV) Vector Production CDMO Market report are Adherent Culture, Suspension Culture

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Adherent Culture
1.2.3 Suspension Culture
1.3 Market by Application
1.3.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Vaccine Development
1.3.3 Gene Therapy
1.3.4 Academic Scientific Research Institution
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Perspective (2021–2032)
2.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Growth Trends by Region
2.2.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Adeno-Associated Virus (AAV) Vector Production CDMO Historic Market Size by Region (2021–2026)
2.2.3 Adeno-Associated Virus (AAV) Vector Production CDMO Forecasted Market Size by Region (2027–2032)
2.3 Adeno-Associated Virus (AAV) Vector Production CDMO Market Dynamics
2.3.1 Adeno-Associated Virus (AAV) Vector Production CDMO Industry Trends
2.3.2 Adeno-Associated Virus (AAV) Vector Production CDMO Market Drivers
2.3.3 Adeno-Associated Virus (AAV) Vector Production CDMO Market Challenges
2.3.4 Adeno-Associated Virus (AAV) Vector Production CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adeno-Associated Virus (AAV) Vector Production CDMO Players by Revenue
3.1.1 Global Top Adeno-Associated Virus (AAV) Vector Production CDMO Players by Revenue (2021–2026)
3.1.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Players (2021–2026)
3.2 Global Top Adeno-Associated Virus (AAV) Vector Production CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Adeno-Associated Virus (AAV) Vector Production CDMO Revenue
3.4 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Concentration Ratio
3.4.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adeno-Associated Virus (AAV) Vector Production CDMO Revenue in 2025
3.5 Global Key Players of Adeno-Associated Virus (AAV) Vector Production CDMO Head Offices and Areas Served
3.6 Global Key Players of Adeno-Associated Virus (AAV) Vector Production CDMO, Products and Applications
3.7 Global Key Players of Adeno-Associated Virus (AAV) Vector Production CDMO, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Adeno-Associated Virus (AAV) Vector Production CDMO Breakdown Data by Type
4.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Historic Market Size by Type (2021–2026)
4.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Forecasted Market Size by Type (2027–2032)
5 Adeno-Associated Virus (AAV) Vector Production CDMO Breakdown Data by Application
5.1 Global Adeno-Associated Virus (AAV) Vector Production CDMO Historic Market Size by Application (2021–2026)
5.2 Global Adeno-Associated Virus (AAV) Vector Production CDMO Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size (2021–2032)
6.2 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2021–2026)
6.4 North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size (2021–2032)
7.2 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2021–2026)
7.4 Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size (2021–2032)
8.2 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region (2021–2026)
8.4 Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size (2021–2032)
9.2 Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2021–2026)
9.4 Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size (2021–2032)
10.2 Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2021–2026)
10.4 Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Details
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.1.4 Thermo Fisher Scientific Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.1.5 Thermo Fisher Scientific Recent Development
11.2 Lonza
11.2.1 Lonza Company Details
11.2.2 Lonza Business Overview
11.2.3 Lonza Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.2.4 Lonza Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.2.5 Lonza Recent Development
11.3 Catalent
11.3.1 Catalent Company Details
11.3.2 Catalent Business Overview
11.3.3 Catalent Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.3.4 Catalent Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.3.5 Catalent Recent Development
11.4 Charles River
11.4.1 Charles River Company Details
11.4.2 Charles River Business Overview
11.4.3 Charles River Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.4.4 Charles River Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.4.5 Charles River Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.5.4 Merck Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.5.5 Merck Recent Development
11.6 SK pharmteco
11.6.1 SK pharmteco Company Details
11.6.2 SK pharmteco Business Overview
11.6.3 SK pharmteco Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.6.4 SK pharmteco Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.6.5 SK pharmteco Recent Development
11.7 Oxford Biomedica
11.7.1 Oxford Biomedica Company Details
11.7.2 Oxford Biomedica Business Overview
11.7.3 Oxford Biomedica Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.7.4 Oxford Biomedica Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.7.5 Oxford Biomedica Recent Development
11.8 AGC Biologics（MolMed）
11.8.1 AGC Biologics（MolMed） Company Details
11.8.2 AGC Biologics（MolMed） Business Overview
11.8.3 AGC Biologics（MolMed） Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.8.4 AGC Biologics（MolMed） Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.8.5 AGC Biologics（MolMed） Recent Development
11.9 Gene Universal
11.9.1 Gene Universal Company Details
11.9.2 Gene Universal Business Overview
11.9.3 Gene Universal Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.9.4 Gene Universal Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.9.5 Gene Universal Recent Development
11.10 Polyplus (Sartorius)
11.10.1 Polyplus (Sartorius) Company Details
11.10.2 Polyplus (Sartorius) Business Overview
11.10.3 Polyplus (Sartorius) Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.10.4 Polyplus (Sartorius) Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.10.5 Polyplus (Sartorius) Recent Development
11.11 CCRM
11.11.1 CCRM Company Details
11.11.2 CCRM Business Overview
11.11.3 CCRM Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.11.4 CCRM Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.11.5 CCRM Recent Development
11.12 FUJIFILM Diosynth Biotechnologies
11.12.1 FUJIFILM Diosynth Biotechnologies Company Details
11.12.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.12.3 FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.12.4 FUJIFILM Diosynth Biotechnologies Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.12.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.13 Biovian
11.13.1 Biovian Company Details
11.13.2 Biovian Business Overview
11.13.3 Biovian Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.13.4 Biovian Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.13.5 Biovian Recent Development
11.14 Miltenyi Bioindustry
11.14.1 Miltenyi Bioindustry Company Details
11.14.2 Miltenyi Bioindustry Business Overview
11.14.3 Miltenyi Bioindustry Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.14.4 Miltenyi Bioindustry Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.14.5 Miltenyi Bioindustry Recent Development
11.15 Aldevron
11.15.1 Aldevron Company Details
11.15.2 Aldevron Business Overview
11.15.3 Aldevron Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.15.4 Aldevron Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.15.5 Aldevron Recent Development
11.16 Takara Bio
11.16.1 Takara Bio Company Details
11.16.2 Takara Bio Business Overview
11.16.3 Takara Bio Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.16.4 Takara Bio Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.16.5 Takara Bio Recent Development
11.17 Yposkesi
11.17.1 Yposkesi Company Details
11.17.2 Yposkesi Business Overview
11.17.3 Yposkesi Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.17.4 Yposkesi Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.17.5 Yposkesi Recent Development
11.18 Genezen
11.18.1 Genezen Company Details
11.18.2 Genezen Business Overview
11.18.3 Genezen Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.18.4 Genezen Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.18.5 Genezen Recent Development
11.19 Exthera
11.19.1 Exthera Company Details
11.19.2 Exthera Business Overview
11.19.3 Exthera Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.19.4 Exthera Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.19.5 Exthera Recent Development
11.20 GenScript ProBio
11.20.1 GenScript ProBio Company Details
11.20.2 GenScript ProBio Business Overview
11.20.3 GenScript ProBio Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.20.4 GenScript ProBio Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.20.5 GenScript ProBio Recent Development
11.21 EurekaBio
11.21.1 EurekaBio Company Details
11.21.2 EurekaBio Business Overview
11.21.3 EurekaBio Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.21.4 EurekaBio Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.21.5 EurekaBio Recent Development
11.22 Obio Technology
11.22.1 Obio Technology Company Details
11.22.2 Obio Technology Business Overview
11.22.3 Obio Technology Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.22.4 Obio Technology Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.22.5 Obio Technology Recent Development
11.23 GeneSail Biotech
11.23.1 GeneSail Biotech Company Details
11.23.2 GeneSail Biotech Business Overview
11.23.3 GeneSail Biotech Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.23.4 GeneSail Biotech Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.23.5 GeneSail Biotech Recent Development
11.24 VectorBuilder
11.24.1 VectorBuilder Company Details
11.24.2 VectorBuilder Business Overview
11.24.3 VectorBuilder Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.24.4 VectorBuilder Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.24.5 VectorBuilder Recent Development
11.25 WuXi ATU
11.25.1 WuXi ATU Company Details
11.25.2 WuXi ATU Business Overview
11.25.3 WuXi ATU Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.25.4 WuXi ATU Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.25.5 WuXi ATU Recent Development
11.26 Ubrigene
11.26.1 Ubrigene Company Details
11.26.2 Ubrigene Business Overview
11.26.3 Ubrigene Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.26.4 Ubrigene Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.26.5 Ubrigene Recent Development
11.27 Porton Biologics
11.27.1 Porton Biologics Company Details
11.27.2 Porton Biologics Business Overview
11.27.3 Porton Biologics Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.27.4 Porton Biologics Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.27.5 Porton Biologics Recent Development
11.28 Pharmaron
11.28.1 Pharmaron Company Details
11.28.2 Pharmaron Business Overview
11.28.3 Pharmaron Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.28.4 Pharmaron Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.28.5 Pharmaron Recent Development
11.29 PackGene Biotechnology
11.29.1 PackGene Biotechnology Company Details
11.29.2 PackGene Biotechnology Business Overview
11.29.3 PackGene Biotechnology Adeno-Associated Virus (AAV) Vector Production CDMO Introduction
11.29.4 PackGene Biotechnology Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
11.29.5 PackGene Biotechnology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Thermo Fisher Scientific
Lonza
Catalent
Charles River
Merck
SK pharmteco
Oxford BioMedica
AGC Biologics（MolMed）
Gene Universal
Polyplus (Sartorius)
CCRM
FUJIFILM Diosynth Biotechnologies
Biovian
Miltenyi Bioindustry
Aldevron
Takara Bio
Yposkesi
Genezen
Exthera
GenScript ProBio
EurekaBio
OBiO Technology
GeneSail Biotech
VectorBuilder
WuXi ATU
Ubrigene
Porton Biologics
Pharmaron
PackGene Biotechnology
List of Tables
 Table 1. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Adherent Culture
 Table 3. Key Players of Suspension Culture
 Table 4. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 5. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 6. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region (US$ Million), 2021–2026
 Table 7. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Region (2021–2026)
 Table 8. Global Adeno-Associated Virus (AAV) Vector Production CDMO Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 9. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Region (2027–2032)
 Table 10. Adeno-Associated Virus (AAV) Vector Production CDMO Market Trends
 Table 11. Adeno-Associated Virus (AAV) Vector Production CDMO Market Drivers
 Table 12. Adeno-Associated Virus (AAV) Vector Production CDMO Market Challenges
 Table 13. Adeno-Associated Virus (AAV) Vector Production CDMO Market Restraints
 Table 14. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue by Players (US$ Million), 2021–2026
 Table 15. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Players (2021–2026)
 Table 16. Global Top Adeno-Associated Virus (AAV) Vector Production CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Adeno-Associated Virus (AAV) Vector Production CDMO Revenue, 2025
 Table 17. Ranking of Global Top Adeno-Associated Virus (AAV) Vector Production CDMO Companies by Revenue (US$ Million) in 2025
 Table 18. Global 5 Largest Players Market Share by Adeno-Associated Virus (AAV) Vector Production CDMO Revenue (CR5 and HHI), 2021–2026
 Table 19. Global Key Players of Adeno-Associated Virus (AAV) Vector Production CDMO, Headquarters and Area Served
 Table 20. Global Key Players of Adeno-Associated Virus (AAV) Vector Production CDMO, Products and Applications
 Table 21. Global Key Players of Adeno-Associated Virus (AAV) Vector Production CDMO, Date of General Availability (GA)
 Table 22. Mergers and Acquisitions, Expansion Plans
 Table 23. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Type (US$ Million), 2021–2026
 Table 24. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Type (2021–2026)
 Table 25. Global Adeno-Associated Virus (AAV) Vector Production CDMO Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 26. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Type (2027–2032)
 Table 27. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Application (US$ Million), 2021–2026
 Table 28. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Application (2021–2026)
 Table 29. Global Adeno-Associated Virus (AAV) Vector Production CDMO Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 30. Global Adeno-Associated Virus (AAV) Vector Production CDMO Revenue Market Share by Application (2027–2032)
 Table 31. North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 32. North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2021–2026
 Table 33. North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2027–2032
 Table 34. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 35. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2021–2026
 Table 36. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2027–2032
 Table 37. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 38. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region (US$ Million), 2021–2026
 Table 39. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Region (US$ Million), 2027–2032
 Table 40. Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 41. Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2021–2026
 Table 42. Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2027–2032
 Table 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 44. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2021–2026
 Table 45. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Country (US$ Million), 2027–2032
 Table 46. Thermo Fisher Scientific Company Details
 Table 47. Thermo Fisher Scientific Business Overview
 Table 48. Thermo Fisher Scientific Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 49. Thermo Fisher Scientific Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 50. Thermo Fisher Scientific Recent Development
 Table 51. Lonza Company Details
 Table 52. Lonza Business Overview
 Table 53. Lonza Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 54. Lonza Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 55. Lonza Recent Development
 Table 56. Catalent Company Details
 Table 57. Catalent Business Overview
 Table 58. Catalent Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 59. Catalent Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 60. Catalent Recent Development
 Table 61. Charles River Company Details
 Table 62. Charles River Business Overview
 Table 63. Charles River Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 64. Charles River Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 65. Charles River Recent Development
 Table 66. Merck Company Details
 Table 67. Merck Business Overview
 Table 68. Merck Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 69. Merck Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 70. Merck Recent Development
 Table 71. SK pharmteco Company Details
 Table 72. SK pharmteco Business Overview
 Table 73. SK pharmteco Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 74. SK pharmteco Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 75. SK pharmteco Recent Development
 Table 76. Oxford Biomedica Company Details
 Table 77. Oxford Biomedica Business Overview
 Table 78. Oxford Biomedica Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 79. Oxford Biomedica Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 80. Oxford Biomedica Recent Development
 Table 81. AGC Biologics（MolMed） Company Details
 Table 82. AGC Biologics（MolMed） Business Overview
 Table 83. AGC Biologics（MolMed） Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 84. AGC Biologics（MolMed） Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 85. AGC Biologics（MolMed） Recent Development
 Table 86. Gene Universal Company Details
 Table 87. Gene Universal Business Overview
 Table 88. Gene Universal Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 89. Gene Universal Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 90. Gene Universal Recent Development
 Table 91. Polyplus (Sartorius) Company Details
 Table 92. Polyplus (Sartorius) Business Overview
 Table 93. Polyplus (Sartorius) Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 94. Polyplus (Sartorius) Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 95. Polyplus (Sartorius) Recent Development
 Table 96. CCRM Company Details
 Table 97. CCRM Business Overview
 Table 98. CCRM Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 99. CCRM Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 100. CCRM Recent Development
 Table 101. FUJIFILM Diosynth Biotechnologies Company Details
 Table 102. FUJIFILM Diosynth Biotechnologies Business Overview
 Table 103. FUJIFILM Diosynth Biotechnologies Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 104. FUJIFILM Diosynth Biotechnologies Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 105. FUJIFILM Diosynth Biotechnologies Recent Development
 Table 106. Biovian Company Details
 Table 107. Biovian Business Overview
 Table 108. Biovian Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 109. Biovian Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 110. Biovian Recent Development
 Table 111. Miltenyi Bioindustry Company Details
 Table 112. Miltenyi Bioindustry Business Overview
 Table 113. Miltenyi Bioindustry Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 114. Miltenyi Bioindustry Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 115. Miltenyi Bioindustry Recent Development
 Table 116. Aldevron Company Details
 Table 117. Aldevron Business Overview
 Table 118. Aldevron Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 119. Aldevron Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 120. Aldevron Recent Development
 Table 121. Takara Bio Company Details
 Table 122. Takara Bio Business Overview
 Table 123. Takara Bio Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 124. Takara Bio Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 125. Takara Bio Recent Development
 Table 126. Yposkesi Company Details
 Table 127. Yposkesi Business Overview
 Table 128. Yposkesi Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 129. Yposkesi Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 130. Yposkesi Recent Development
 Table 131. Genezen Company Details
 Table 132. Genezen Business Overview
 Table 133. Genezen Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 134. Genezen Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 135. Genezen Recent Development
 Table 136. Exthera Company Details
 Table 137. Exthera Business Overview
 Table 138. Exthera Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 139. Exthera Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 140. Exthera Recent Development
 Table 141. GenScript ProBio Company Details
 Table 142. GenScript ProBio Business Overview
 Table 143. GenScript ProBio Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 144. GenScript ProBio Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 145. GenScript ProBio Recent Development
 Table 146. EurekaBio Company Details
 Table 147. EurekaBio Business Overview
 Table 148. EurekaBio Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 149. EurekaBio Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 150. EurekaBio Recent Development
 Table 151. Obio Technology Company Details
 Table 152. Obio Technology Business Overview
 Table 153. Obio Technology Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 154. Obio Technology Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 155. Obio Technology Recent Development
 Table 156. GeneSail Biotech Company Details
 Table 157. GeneSail Biotech Business Overview
 Table 158. GeneSail Biotech Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 159. GeneSail Biotech Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 160. GeneSail Biotech Recent Development
 Table 161. VectorBuilder Company Details
 Table 162. VectorBuilder Business Overview
 Table 163. VectorBuilder Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 164. VectorBuilder Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 165. VectorBuilder Recent Development
 Table 166. WuXi ATU Company Details
 Table 167. WuXi ATU Business Overview
 Table 168. WuXi ATU Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 169. WuXi ATU Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 170. WuXi ATU Recent Development
 Table 171. Ubrigene Company Details
 Table 172. Ubrigene Business Overview
 Table 173. Ubrigene Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 174. Ubrigene Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 175. Ubrigene Recent Development
 Table 176. Porton Biologics Company Details
 Table 177. Porton Biologics Business Overview
 Table 178. Porton Biologics Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 179. Porton Biologics Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 180. Porton Biologics Recent Development
 Table 181. Pharmaron Company Details
 Table 182. Pharmaron Business Overview
 Table 183. Pharmaron Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 184. Pharmaron Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 185. Pharmaron Recent Development
 Table 186. PackGene Biotechnology Company Details
 Table 187. PackGene Biotechnology Business Overview
 Table 188. PackGene Biotechnology Adeno-Associated Virus (AAV) Vector Production CDMO Product
 Table 189. PackGene Biotechnology Revenue in Adeno-Associated Virus (AAV) Vector Production CDMO Business (US$ Million), 2021–2026
 Table 190. PackGene Biotechnology Recent Development
 Table 191. Research Programs/Design for This Report
 Table 192. Key Data Information from Secondary Sources
 Table 193. Key Data Information from Primary Sources
 Table 194. Authors List of This Report


List of Figures
 Figure 1. Adeno-Associated Virus (AAV) Vector Production CDMO Picture
 Figure 2. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Type: 2025 vs 2032
 Figure 4. Adherent Culture Features
 Figure 5. Suspension Culture Features
 Figure 6. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size by Application (US$ Million), 2021–2032
 Figure 7. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Application: 2025 vs 2032
 Figure 8. Vaccine Development Case Studies
 Figure 9. Gene Therapy Case Studies
 Figure 10. Academic Scientific Research Institution Case Studies
 Figure 11. Others Case Studies
 Figure 12. Adeno-Associated Virus (AAV) Vector Production CDMO Report Years Considered
 Figure 13. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 14. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 15. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Region: 2025 vs 2032
 Figure 16. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Players in 2025
 Figure 17. Global Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 18. The Top 10 and 5 Players Market Share by Adeno-Associated Virus (AAV) Vector Production CDMO Revenue in 2025
 Figure 19. North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 20. North America Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Country (2021–2032)
 Figure 21. United States Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. Canada Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 23. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. Europe Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Country (2021–2032)
 Figure 25. Germany Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. France Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. U.K. Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. Italy Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Russia Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Ireland Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Asia-Pacific Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Region (2021–2032)
 Figure 33. China Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. Japan Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. South Korea Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Southeast Asia Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. India Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Australia & New Zealand Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Latin America Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Country (2021–2032)
 Figure 41. Mexico Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Brazil Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 43. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Middle East & Africa Adeno-Associated Virus (AAV) Vector Production CDMO Market Share by Country (2021–2032)
 Figure 45. Israel Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. Saudi Arabia Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 47. UAE Adeno-Associated Virus (AAV) Vector Production CDMO Market Size YoY Growth (US$ Million), 2021–2032
 Figure 48. Thermo Fisher Scientific Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 49. Lonza Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 50. Catalent Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 51. Charles River Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 52. Merck Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 53. SK pharmteco Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 54. Oxford Biomedica Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 55. AGC Biologics（MolMed） Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 56. Gene Universal Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 57. Polyplus (Sartorius) Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 58. CCRM Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 59. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 60. Biovian Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 61. Miltenyi Bioindustry Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 62. Aldevron Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 63. Takara Bio Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 64. Yposkesi Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 65. Genezen Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 66. Exthera Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 67. GenScript ProBio Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 68. EurekaBio Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 69. Obio Technology Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 70. GeneSail Biotech Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 71. VectorBuilder Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 72. WuXi ATU Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 73. Ubrigene Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 74. Porton Biologics Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 75. Pharmaron Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 76. PackGene Biotechnology Revenue Growth Rate in Adeno-Associated Virus (AAV) Vector Production CDMO Business (2021–2026)
 Figure 77. Bottom-up and Top-down Approaches for This Report
 Figure 78. Data Triangulation
 Figure 79. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Global Viral Vector Manufacturing CDMO Services Market Research Report 2024
Global Cell and Gene Therapy CDMO Services Market Research Report 2024
Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization CDMO Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Biopharmaceutical CDMO Market Research Report 2025
Global AAV Production Service Market Research Report 2024
Global Biopharmaceutical and Bio CDMO Market Research Report 2024
Global Cell Therapy CDMO Services Market Research Report 2025
Global Biopharmaceutical CDMO Service Market Research Report 2024
Global mRNA CDMO Service Market Research Report 2024
Global Contract Dose Manufacturing Market Insights Forecast to 2030
Global Plasmid DNA CDMO Service Market Research Report 2024
Global Bio Contract Development and Manufacturing Organizations CDMOs Market Insights Forecast to 2030
Global Chemical CDMO Market Research Report 2024
Global Pharmaceutical Contract Development and Manufacturing Organization Market Research Report 2025
Global Full Service CDMO Market Research Report 2024
Global Pharmaceutical CDMO Market Research Report 2025
Global Oligonucleotide CDMO Market Research Report 2025
CGT CDMO Market
Global Adeno Associated Virus Production Market Research Report 2024
Global Oligonucleotide Drug CDMO Services Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions